Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663560 | 0.89 | ALDH1A1 (0.33) | POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL15194472 | 0.75 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL15194564 | 0.75 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL9726985 | 0.75 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL20217613 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1206633 | 0.73 | SIGMAR1 (0.59) | POLBALDH1A1 | |
| SCHEMBL9371857 | 0.72 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL15194407 | 0.71 | ALDH1A1 (0.59) | ALDH1A1 | |
| SCHEMBL9853462 | 0.70 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL1350511 | 0.70 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| CN-113924092-B | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024208228-A1 | NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-10-10 | — | — | WO | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113924092-A | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | POLB 627/4885SMN1; SMN2 2606/4885ALDH1A1 1805/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | POLB 627/4885SMN1; SMN2 2606/4885ALDH1A1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.